The Filing Desk

Amphstar Pharmaceuticals vs Kiniksa Pharmaceuticals

Amphstar Pharmaceuticals AMPH · Kiniksa Pharmaceuticals KNSA · Pharmaceuticals

Amphstar Pharmaceuticals reported revenue of $720 million in fiscal 2025, about the same as Kiniksa Pharmaceuticals' $678 million in fiscal 2025. Amphstar Pharmaceuticals' revenue fell 1.6% in its latest year, and Kiniksa Pharmaceuticals' grew 60.1%. Amphstar Pharmaceuticals had an operating margin of 19.5%, against 11.4% at Kiniksa Pharmaceuticals. Free cash flow was $121 million at Amphstar Pharmaceuticals and $136 million at Kiniksa Pharmaceuticals.

Side by side

Amphstar PharmaceuticalsKiniksa Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$720M$678M
Revenue growth−1.6%60.1%
Revenue growth a year, last 5 years15.5%—
Gross margin49.5%88.5%
Operating margin19.5%11.4%
Net margin13.6%8.7%
Free cash flow$121M$136M
Free cash flow margin16.8%20.1%
Return on capital9.9%—
Net debt to EBITDA1.7x—
Dividends and buybacks$76M$0M
Change in diluted share count−7.4%10.6%
Last close$29.37$96.33
P/E at the last close13.4×73.5×
Insider trades, last 12 monthssold $2.1 millionsold $45.1 million
Piotroski F-score6 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Amphstar PharmaceuticalsKiniksa Pharmaceuticals
Operating margin
Percent of revenue
Amphstar PharmaceuticalsKiniksa Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Amphstar PharmaceuticalsKiniksa Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Amphstar Pharmaceuticals and Kiniksa Pharmaceuticals pages.